Reprieve Cardiovascular Raises $61M to Fund Pivotal Heart Failure Trial

Reprieve secures $61m for ADHF system trial

Reprieve Cardiovascular has closed an oversubscribed Series B financing round, raising $61m, for the trial of the Reprieve system.The post Reprieve secures $61m for ADHF system trial appeared first on Medical Device Network.

Reprieve Cardiovascular announces funding and trial enrolment milestones - Cardiovascular News

Reprieve Cardiovascular has announced the close of a US$61 million Series B financing, alongside enrolment of the first patient in its global FASTR II pivotal trial, evaluating the efficacy of its Reprieve system compared to optimal diuretic therapy in patients hospitalised with acute decompensated heart failure (ADHF). The oversubscribed financing round was led by Deerfield Management and joined by Arboretum Ventures, Lightstone Ventures, Sante…

Reprieve Cardiovascular Raises $61M to Fund Pivotal Heart Failure Trial

What You Should Know:  – Reprieve Cardiovascular, a clinical-stage company secures $61M in Series B funding led by Deerfield Management and included participation from several other investors, such as Arboretum Ventures, Lightstone Ventures, and an undisclosed strategic investor. – The funding round, which combines equity investment with a debt facility will be used to support the rapid execution of the global FASTR II pivotal clinical trial and…